Abou-Donia M B, Lapadula D M
Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27710.
Annu Rev Pharmacol Toxicol. 1990;30:405-40. doi: 10.1146/annurev.pa.30.040190.002201.
Some organophosphorus compounds produce neurologic dysfunctions, known as OPIDN, after a delay period that is accompanied by neuropathic damage in the central and peripheral nervous systems. This group of chemicals may be divided into two classes, Type I and II, based on chemical structure, species selectivity, age sensitivity, the length of latent period, clinical signs, morphology and distribution of neuropathologic lesions, protection with phenylmethyl sulfonyl fluoride, inhibition of neurotoxic esterase, and effect on catecholamine secretion from bovine adrenome-dullary chromaffin cells. The importance of this effect is underlined by the fact that incidents involving more than 40,000 cases of OPIDN in humans have been documented from 1899 to 1989. Most of these compounds are direct or indirect inhibitors of AChE, and produce acute cholinergic effects. Neurologic deficits are characterized by three phases: progressive, stationary, and improvement. Prognosis of OPIDN depends on the extent of damage of the nervous system. Improvement or even recovery of functions may follow mild cases, whereas severe toxicity results in long-lasting neurologic dysfunctions reflecting spinal cord damage. Recent studies have shown that delayed neurotoxic organophosphorus compounds interact with Ca2+/calmodulin kinase II (CaM kinase II), an enzyme responsible for the endogenous phosphorylation of cytoskeletal proteins, i.e. microtubules, neurofilaments, and MAP-2. This leads to an increased activity of CaM kinase II and enhanced phosphorylation of cytoskeletal elements, and eventually in the disassembly of cytoskeletal proteins. The dissociation of cytoskeletal proteins causes increased fast axonal transport in the treated animals resulting in the accumulation of altered cytoskeletal elements in the distal portions of the axon. Abnormal tubulin and neurofilaments are transformed into filamentous polymers and undergo condensation and dissolution. Concomitantly, proliferated endoplasmic reticulum and accumulated mitochondria degenerate and release Ca2+ ions. This leads to Ca2(+)-activated proteolysis of the cytoskeleton and interruption of ionic balance across the axonal membrane resulting in the uptake of water and axonal swelling, which subsequently degenerates. A similar mechanism may cause secondary myelin degeneration.
一些有机磷化合物在一段延迟期后会产生神经功能障碍,即有机磷中毒性神经病(OPIDN),同时伴有中枢和周围神经系统的神经病变。根据化学结构、物种选择性、年龄敏感性、潜伏期长短、临床症状、神经病理损伤的形态和分布、苯甲基磺酰氟的保护作用、神经毒性酯酶的抑制作用以及对牛肾上腺髓质嗜铬细胞儿茶酚胺分泌的影响,这类化学物质可分为I型和II型。1899年至1989年期间,已记录到涉及人类40000多例OPIDN病例的事件,这突出了这种影响的重要性。这些化合物大多是乙酰胆碱酯酶(AChE)的直接或间接抑制剂,并产生急性胆碱能效应。神经功能缺损具有三个阶段:进行性、静止性和改善期。OPIDN的预后取决于神经系统的损伤程度。轻度病例可能会改善甚至恢复功能,而严重中毒则会导致反映脊髓损伤的长期神经功能障碍。最近的研究表明,延迟性神经毒性有机磷化合物与钙调蛋白激酶II(CaM激酶II)相互作用,该酶负责细胞骨架蛋白(即微管、神经丝和微管相关蛋白2)的内源性磷酸化。这导致CaM激酶II活性增加和细胞骨架成分磷酸化增强,最终导致细胞骨架蛋白解体。细胞骨架蛋白的解离导致治疗动物的快速轴突运输增加,导致轴突远端改变的细胞骨架成分积累。异常的微管蛋白和神经丝转变为丝状聚合物,并经历凝聚和溶解。同时,内质网增生和线粒体积累退化并释放钙离子。这导致细胞骨架的钙激活蛋白水解和轴突膜离子平衡中断,导致水分摄取和轴突肿胀,随后轴突退化。类似的机制可能导致继发性髓鞘变性。